These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28463161)

  • 1. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
    Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
    Basch E; Dueck AC; Rogak LJ; Minasian LM; Kelly WK; O'Mara AM; Denicoff AM; Seisler D; Atherton PJ; Paskett E; Carey L; Dickler M; Heist RS; Himelstein A; Rugo HS; Sikov WM; Socinski MA; Venook AP; Weckstein DJ; Lake DE; Biggs DD; Freedman RA; Kuzma C; Kirshner JJ; Schrag D
    JAMA Oncol; 2017 Aug; 3(8):1043-1050. PubMed ID: 28208174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
    JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bennett AV; Dueck AC; Mitchell SA; Mendoza TR; Reeve BB; Atkinson TM; Castro KM; Denicoff A; Rogak LJ; Harness JK; Bearden JD; Bryant D; Siegel RD; Schrag D; Basch E;
    Health Qual Life Outcomes; 2016 Feb; 14():24. PubMed ID: 26892667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
    Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
    Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
    Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
    JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
    Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
    JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.
    Basch E; Dueck AC; Rogak LJ; Mitchell SA; Minasian LM; Denicoff AM; Wind JK; Shaw MC; Heon N; Shi Q; Ginos B; Nelson GD; Meyers JP; Chang GJ; Mamon HJ; Weiser MR; Kolevska T; Reeve BB; Bruner DW; Schrag D
    J Clin Oncol; 2018 Sep; 36(31):JCO2018788620. PubMed ID: 30204536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Kluetz PG; Chingos DT; Basch EM; Mitchell SA
    Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
    Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
    Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
    J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
    J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).
    Caminiti C; Bryce J; Riva S; Ng D; Diodati F; Iezzi E; Sparavigna L; Novello S; Porta C; Del Mastro L; Procopio G; Cinieri S; Falzetta A; Calabrò F; Lorusso V; Cogoni AA; Tortora G; Maruzzo M; Passalacqua R; Cognetti F; Adamo V; Capelletto E; Ferrari A; Bagnalasta M; Bassi M; Nicelli A; De Persis D; D'Acunti A; Iannelli Patient E; Perrone F; Mitchell SA
    Tumori; 2023 Jun; 109(3):324-334. PubMed ID: 35674125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Arnold B; Mitchell SA; Lent L; Mendoza TR; Rogak LJ; Barragán NM; Willis G; Medina M; Lechner S; Penedo FJ; Harness JK; Basch EM;
    Support Care Cancer; 2016 Jul; 24(7):2843-51. PubMed ID: 26838022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
    Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
    Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR
    Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.
    Davis S; Edwards T; Norcross L; Fehnel S; Beaudet A; Eckart M; Fastenau J
    J Patient Rep Outcomes; 2023 Dec; 7(1):134. PubMed ID: 38108945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
    Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
    J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.